We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... Analysts project that Eylea’s sales will face continued pressure, potentially leading to a substantial decline in market share. The slower-than-expected ...